BriaCell Therapeutics Corp. (BCTX) stock prices were down by a marginal 2.75% as of the market closing on June 1st, 2021, bringing the price per share up to USD$3.18 at the end of the trading day. Subsequent current market fluctuations have seen the stock skyrocket by 99.69% to hit USD$6.35.
OS Update
The clinical stage biotechnology company provided an update on June 2nd, 2021 on the overall survival (OS) data on its previously announced advanced breast cancer patients. These women were administered BCTX’s lead candidate Bria-IMT as monotherapy, as well as in conjunction with checkpoint inhibitors. These inhibitors include prembrulizumab and Incyte’s retifanlimab
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
Read More
HLA-Typing
The body’s immune response is triggered by cells with human leukocyte antigen (HLA) on their surface. BCTX’s proprietary immunotherapy treatment appears most effective when the patient’s HLA-type corresponds to Bria-IMT, allowing the company to potentially identify patients that are most likely to respond. HLA-typing is a highly accessible test, which is simple to use and available widely.
Top Responder Overview
September 19th, 2019 saw the emphasis by BCTX on a patient’s positive response to BriaCell’s treatment, with a follow-up on January 13th, 2020. Before the administering of BCTX’s treatment, the patient had received 12 regimens with 16 agents. Despite this, her condition worsened, resulting in a gruesome orbital tumor, which metastasized behind her left eye to the extent of causing her eye to bulge from its socket.
Success of BCTX Treatment
Six months after the commencement of BCTX’s treatment, the patient’s orbital tumor was reported to have been completely eliminated. This resulted in the patient surviving for over 21 months, which is a monumentally significant clinical benefit.
Scope of Treatment
The CEO of BCTX highlighted the failure of currently available treatments to adequately address the fight against advanced breast cancer that women have been diagnosed with. To this end, the company was pleased to announce the success of its immunotherapy regimen, which serves to offer clinical benefits for patients in dire need of new therapy options.
Future Outlook for BCTX
Armed with the massive surge in stock price, BCTX is poised to capitalize on this recent development and facilitate the proliferation of their treatment. Following the expansion and consolidation of their footprint, the company is hopeful for a continued trajectory of success. Current and potential investors are hopeful that management will be able to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.